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740 The Journal of Thoracic and CardioBackground: Severe degree of pulmonary vascular hypoplasia remains a major
limitation in congenital heart surgery. Considering the potential effect of gene
transfer with hepatocyte growth factor to induce the angiogenesis in the lung, we
assessed the effects of hepatocyte growth factor gene transfer in neonatal porcine
lung with pulmonary vascular hypoplasia to achieve treatment for severe pulmonary
vascular hypoplasia.
Methods: The model of pulmonary vascular hypoplasia was introduced with left
pulmonary artery banding in piglet lung. After 7 days of pulmonary artery banding,
piglets were transfected selectively to the left lung via the left pulmonary artery with
a hemagglutinating virus of Japan E vector bearing the cDNA encoding human
hepatocyte growth factor (H group) or control vector (C group).
Results: Seven days after the transfection, selective angiography of the left pulmo-
nary artery showed the progression of left pulmonary vascular hypoplasia of the left
lung in the C group but a significant attenuation of left pulmonary vascular
hypoplasia in the H group. A right pulmonary artery occlusion test showed a marked
increase in right ventricular systolic pressure in the C group, but this was signifi-
cantly attenuated in the H group (C: 22.0  2.9, H: 13.0  2.7 mm Hg; P  .05).
Histologic examination revealed that hepatocyte growth factor gene transfection
increased the pulmonary vasculature in the left lung.
Conclusions: Our results demonstrated that gene transfer of hepatocyte growth
factor via the pulmonary artery showed the angiogenic effects in porcine model of
pulmonary vascular hypoplasia after pulmonary artery banding.
T he feasibility of a definitive surgical repair of cyanotic congenitalheart disease largely depends on the development of the pulmonaryvasculature. Since the introduction of the Blalock-Taussig shunt,1the strategy for treatment of hypoplastic pulmonary artery has beenestablished, and the surgical advances that followed improved theclinical outcomes of patients with hypoplastic pulmonary artery.2-5
However, a group of patients still remains who survive palliation but cannot undergo
definitive surgery and who require further treatment for progressive cyanosis.6
These patients are usually associated with hypoplasia within the entire pulmonary
vascular bed as well as hypoplasia of central pulmonary arteries. In this context,
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Dvarious growth factors indicating angiogenesis can be ap-
plied as a treatment for ischemic coronary and peripheral
artery disease,7,8 so-called “therapeutic angiogenesis.”
Hepatocyte growth factor (HGF), which was originally
purified and cloned as a potent mitogen for hepatocytes,9
acts as an organotrophic factor for the regeneration and
protection of organs, including the liver,10 kidney,11
heart,12,13 and lung.14,15 Furthermore, HGF has an angio-
genic effect on the ischemic heart16 and limb17 and the
normal rat lung.18 On the basis of the above information, we
hypothesized that in vivo gene transfection of the lung with
HGF may have therapeutic effects for severe pulmonary
vascular hypoplasia. In this study, we investigated the ther-
apeutic potential of in vivo gene transfection with HGF
using the piglet model of pulmonary vascular hypoplasia.
Materials and Methods
Animal Care
This study was carried out under the supervision of the Animal
Research Committee in accordance with the Guidelines on Animal
Experiments of Osaka University Medical School and the Japanese
Figure 1. Evaluation of pulmonary vascular hypoplas
angiogram. Selective left pulmonary arteriogram 7 da
vascular hypoplasia (right) compared with the norma
Changes in right ventricular systolic pressure (RVP) r
Each value represents the mean  SEM (n  4). #P <
Figure 2. Angiographic changes in the pulmonary a
transfected with the HGF gene (B) or mock vector (A)Government Animal Protection and Management Law.
The Journal of ThoraciConstruction of Plasmid Bearing the Human HGF Gene
To prepare an HGF expression vector, the cDNA for human HGF
was inserted into the Not I site of the pUC-SR expression vector
plasmid.19 In this plasmid, expression of the HGF cDNA is reg-
ulated under the control of the SR promoter.20 We also con-
structed a control expression vector lacking the HGF gene.
Preparation of Hemagglutinating Virus of Japan
Envelope Vector
The preparation of the hemagglutinating virus of Japan (HVJ)
envelope vector is described by Kaneda and associates.21 In brief,
stored virus was suspended in 30 L of TE solution (10 mmol/L
Tris-HCl, pH 8.0, 1 mmol/L EDTA). The virus suspension was
mixed with 200 g of plasmid DNA and 5 L of detergent. The
mixture was spun at 18,500g for 15 minutes at 4°C. After the pellet
had been washed with 1 mL balanced salt solution to remove the
detergent and unincorporated DNA, the envelope vector was sus-
pended in 1 mL of phosphate-buffered saline (PBS) solution and
used for subsequent experiments.
Surgical Approach and Left Pulmonary Artery Banding
Female piglets weighing 5 kg were anesthetized by intraperitoneal
left pulmonary artery banding (PAB). A, Pulmonary
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Dmg/kg xylazine (Bayer AG, Leverkusen, Germany), and 5 mg/kg
propionylpromazine (Bayer). The piglets were intubated and ven-
tilated with a ventilator (MERA MD-705XL, Medical Instrument
Mfg Co, Ltd, Tokyo, Japan). Breaths were administered at a rate of
30 per minute with a tidal volume of 130 mL with 40 % oxygen
and 2% Sevofrane (Maruishi Pharmaceutical. Co, Ltd, Osaka,
Japan). The piglets then underwent left thoracotomy. After the
azygos vein was divided, the left pulmonary artery was dissected
out and banded with polyester tape (circumference: 8 mm). After
hemostasis, the thoracotomy was closed in 3 layers. The piglets
were extubated and allowed to recover in a warm, oxygenated
environment.
Gene Transfection of the Left Lung via the Pulmonary
Artery
Seven days after pulmonary artery banding, the piglets were anesthe-
tized again and underwent lower partial median thoracotomy. A
balloon catheter (CI-213; Harmac Medical Products, Inc, Buffalo,
NY) was inserted from the right ventricle into the left main pulmonary
artery, where it was secured, and then selective left pulmonary artery
angiography was performed. Next, the HVJ envelope-plasmid com-
plex (20 mL, containing 2 mg of cDNA) was infused via the catheter,
after the occlusion of the left pulmonary artery flow by balloon
inflation for 3 minutes. The catheter was then removed, the sternot-
omy was closed, and the soft tissues and skin were closed in layers.
The animal was allowed to recover in a warm, oxygenated environ-
ment. The expression vector bearing the human HGF cDNA was
transfected into 12 piglets (H group) and the vector without HGF was
transfected into another 12 piglets, which served as the controls (C
group). In addition, 4 piglets, which received no treatment, served as
normal controls.
Pulmonary Angiography and Pulmonary Artery
Occlusion Test
To assess the change in pulmonary vasculature and pulmonary
resistance in the left lung after gene transfection, we performed a
pulmonary angiography and a pulmonary artery clamp test that
was designed on the basis of our clinical experience.22 In brief,
piglets were anesthetized, intubated, and ventilated again. A mid-
line thoracotomy was carefully performed. A balloon catheter was
inserted from the right ventricle and secured in the left main
pulmonary artery. Left pulmonary angiography was then per-
formed. The same catheter was then secured in the right main
pulmonary artery, and the balloon was inflated, which occluded the
right pulmonary artery. The right ventricular systolic pressure
before and after occlusion was measured by puncture with a
22-gauge needle connected to a transducer (Terumo Medical Cor-
poration, Somerset, NJ) and polygraph system (Nihon Kohden Co,
Tokyo, Japan). This measurement was performed 3 times, and the
increase in right ventricular pressure (RVP) was calculated. The
heart and lungs were then resected en bloc, and the lungs were
cleared of blood by infusing cold PBS solution through a catheter
positioned in the main pulmonary artery. For enzyme-linked im-
munoassay, blocks of lung tissue were obtained from all samples
in each group. Then, all tissue samples subjected to histologic
analysis were fixed in ethanol instilled at 20 mm Hg of pressure
thorough the main stem bronchus and kept for 24 hours on a
constant pressure system. Four piglets in each group were evalu-
742 The Journal of Thoracic and Cardiovascular Surgery ● Apriated 4, 7, and 14 days after the transfection. The surgeon perform-
ing the procedure was blinded to the treatment status (ie, HGF or
control) of each animal until the end of the study.
Immunohistochemical Analysis
Tissue specimens obtained from the hilum of the left lung were
fixed in ethanol, embedded in paraffin, and sectioned. The sections
were immunohistochemically stained with a rabbit polyclonal an-
tibody against factor VIII, which is a specific marker of endothelial
cells. The number of factor VIII–positive arteries that were more
than 100 m in diameter was counted under a microscope for 10
randomly selected fields per specimen. The arterial density was
determined as the average number of factor VIII–positive arteries
along 1 terminal bronchiole per 1 mm2. The pathologist reviewing
the sections was blinded to the experimental group until the end of
the analysis.
Assay of Human HGF
To perform the enzyme-linked immunosorbent assay (ELISA) of
human HGF in the treated lung, blocks of the lung from each group
were obtained 4, 7, and 14 days after gene transfection. The level
of human HGF in the lung was estimated with an anti-human HGF
monoclonal antibody (Institute of Immunology, Tokyo, Japan).
The antibody that we used in the ELISA specifically detects human
HGF but not endogenous piglet HGF.
Statistical Analysis
All values are expressed as the mean  SEM. The statistical
differences in data obtained by pressure assessment after pulmo-
nary artery banding and ELISA were determined by the Student t
test. Statistical differences in the other data were assessed by
1-way analysis of variance (ANOVA) followed by the Bonferroni
post hoc test.
Results
Evaluation of Pulmonary Vascular Hypoplasia After
Pulmonary Artery Banding
Seven days after pulmonary artery banding, selective left
pulmonary arteriography demonstrated marked decrease in
pulmonary vasculature after pulmonary artery banding com-
pared with the normal control (Figure 1, A). Diminishing
peripheral pulmonary arteries and dilation of left main pul-
monary artery were featured in this model. Right pulmonary
artery occlusion test, in which the left lung received total
blood flow from the right ventricle, also revealed a signif-
icant increase of right ventricular systolic pressure 7 days
after the procedure compared with the normal control (Fig-
ure 1, B).
Evaluation of HGF Gene Transfection
Next, we evaluated the effect of HGF gene transfer in this
model. An enzyme immunoassay demonstrated a human
HGF protein expression in all of the HGF-transfected lungs
4 and 7 days after transfection (0.35  0.02, 0.37  0.02
ng/g tissue, respectively), whereas it was not detected in the
control lung (P  .01 vs control; Student t test). Human
l 2005
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DHGF could not be detected on days 14 in either HGF-
transfected lungs or control lungs.
Selective left pulmonary arteriogram demonstrated pro-
gressive pulmonary vascular hypoplasia of the left lung in
the control group (Figure 2, A, Video 1) 7 days after gene
transfection, whereas in the piglets that received HGF gene
therapy, left pulmonary angiogram demonstrated marked
increase in pulmonary vasculature of the left lung (Figure 2,
B, Video 1). These angiographic differences were observed
at 4 and 14 days after gene transfection.
A right pulmonary artery occlusion test revealed that the
RVP had not changed after gene transfection in the C
group but had significant attenuation in the H group. This
significant difference continued for 14 days after gene trans-
fection (Figure 3).
Histologic examination revealed that there was an in-
crease of the number of pulmonary arteries (Figure 4, B)
compared with the control group (Figure 4, A). Further-
more, a marked increase of factor VIII–positive pulmonary
arteries along a single terminal bronchiole was observed in
the H group (Figure 4, C) on days 4, 7, and 14 after gene
transfection.
Discussion
In the present study, we demonstrated that in vivo transfec-
tion of the lung with the HGF gene increased pulmonary
vasculature in a piglet model of pulmonary vascular hyp-
oplasia. This conclusion is supported by the following evi-
dence: (1) pulmonary arteriography showed the increase of
pulmonary vasculature; (2) the number of factor VIII–posi-
Figure 3. Changes in the pulmonary vascular resistance of the
left lung by a right pulmonary artery occlusion test. The increase
in right ventricular pressure (RVP) was attenuated in H group on
days 4, 7, and 14 after gene transfection (G.T.). Each value rep-
resents the mean  SEM of values obtained using 4 piglets at
each time point in each group. ##P < .01, #P < .05 versus control
(CON) (ANOVA). The black bar indicates HGF gene–transfected
lung (n  4); the white bar indicates control lung (n  4).tive pulmonary arteries significantly increased; (3) left pul-
The Journal of Thoracimonary vascular resistance, assessed by the pulmonary ar-
tery occlusion test, decreased after HGF gene transfection.
We evaluated pulmonary arteries in the left lung after
transfection of HGF gene, both angiographically and histo-
logically. There was no angiographic or histologic vascular
abnormality, such as pulmonary arteriovenous fistula, and
no significant decrease in oxygen saturation in the arterial
blood after HGF gene transfection (data not shown). We
could not see any general side effects during or after gene
transfection of HGF. The pulmonary arteries induced by
HGF gene transfection in this piglet model of pulmonary
vascular hypoplasia seemed to be a relatively large size
compared with that reported in coronary12 or peripheral17
artery disease. Our angiographic data showed an increase in
the number of pulmonary arteries, and histologic analysis
revealed an increase in the number of pulmonary arteries in
the transfected lung. Further investigation is needed to con-
firm the mechanisms of this vascular development.
As to the model of pulmonary vascular hypoplasia, there is
no established animal model for creating pulmonary vascular
hypoplasia. As Lambert and colleagues23 reported the useful-
ness of left pulmonary artery banding for creating pulmonary
vascular hypoplasia, we performed left pulmonary artery band-
ing in neonatal piglets. In this model, angiographic and histo-
logic analysis demonstrated significant vascular change 7 days
after banding and showed progressive pulmonary vascular
hypoplasia. Then, we performed HGF gene transfection 7 days
postoperatively. Our histologic data showed pulmonary angio-
genesis consistent with the result of Lambert and associates,23
and angiographic data demonstrated physiologic increase of
pulmonary vasculature even in the presence of left pulmonary
artery banding. This suggests that a reduced but persisting
blood supply is sufficient for peripheral pulmonary vascular
development in the presence of overexpressed HGF. HGF
gene transfection decreased the pulmonary vascular resistance
when blood flow increased, even in the presence of left pul-
monary artery occlusion. About this mechanism, we speculate
that when pulmonary blood flow is increased, pulmonary vas-
cular resistance largely depends not on the central pulmonary
artery size but on the compliance of peripheral pulmonary
vasculature, based on our clinical experience22 and another
report.24 To compare the effect of HGF gene transfection with
that of debanding or placement of a shunt to the left pulmonary
artery is a great concern. Further investigation is mandatory to
evaluate how this strategy contributes to the clinical aspects for
the treatment of severe pulmonary vascular hypoplasia.
The main limitation of this study is that our data were
obtained from piglets that had received pulmonary artery
banding after birth. There are some differences in the con-
dition of the pulmonary vasculature between this model and
lungs that are clinically diseased from the fetal period, such
as in the tissue levels of growth factors and endothelial
function. Further investigation under conditions that repre-
c and Cardiovascular Surgery ● Volume 129, Number 4 743
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Dsent the damaged or underdeveloped lung, including pul-
monary banding in the gestational period, will need to be
carried out. However, this model may be relevant to the
same situation of pulmonary vascular disease clinically
evaluated.
Used in combination with a conventional surgical pro-
cedure such as systemic-pulmonary shunt and unifocaliza-
tion of major aortopulmonary collateral arteries, this strat-
egy may increase pulmonary blood flow and decrease the
pulmonary vascular resistance. Synergistic effects of these
strategies should be expected and also investigated using a
combination therapy of shunt and gene transfection. Al-
though further investigation is required to confirm the ther-
apeutic potential of this strategy, our results showed the
possibility for treating patients with severe pulmonary vas-
cular hypoplasia.
In summary, in vivo gene transfection of the lung with
Figure 4. Changes in the number of arteries in the left l
in the left lung transfected with HGF gene (B) or mock
A, B:100.) C, Number of pulmonary arteries along the
of values obtained using 4 piglets in each group. #P
gene–transfected lung (n  4); the white bar indicateHGF by means of pulmonary arterial injection of the HVJ
744 The Journal of Thoracic and Cardiovascular Surgery ● Aprienvelope vector increased pulmonary vasculature angio-
graphically, ameliorated the increase in right ventricular
pressure when the right pulmonary artery was occluded, and
increased the histologic number of pulmonary arteries, sug-
gesting the development of left pulmonary vasculature.
These data suggest that gene transfection with HGF may
become a new therapy for patients with severely hypoplastic
pulmonary vasculature.
We thank Mrs Masako Yokoyama and Mr Shigeru Matsumi for
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